（股份代號：1696） 董事名單與其角色及職能 復銳醫療科技有限公司董事會（「董事會」）成員載列如下（自二零二五年六月二十四 日起生效）： 執行董事 劉毅先生 （主席） Lior Moshe DAYAN先生 （首席執行官） 李家宏先生 （首席財務官） 非執行董事 吳以芳先生 馮蓉麗女士 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） 方香生先生 陳志峰先生 陳怡芳女士 廖啟宇先生 相關董事委員會成員載列如下（自二零二五年三月十九日起）： | 董事 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 劉毅先生 | | M | C | | Lior Moshe DAYAN先生 | | | | | 李家宏先生 | | | | | 吳以芳先生 | | | | | 馮蓉麗女士 | | | | | 方香生先生 | C | | M | | 陳志峰先生 | | C | | | 陳怡芳女士 | M | | M | | 廖啟宇先生 | M | M | | 附註： C 委員會主席 M 委員會成員 香港， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 董事會附屬委員會組成變動 Sisram Medical Ltd復銳醫療科技有限公司*董事（「董事」）會（「董事會」）宣佈，自 二零二五年六月二十四日起： 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 劉毅 香港，二零二五年六月二十四日 於本公告日期，董事會包括執行董事劉毅先生、Lior Moshe DAYAN先生及李家 宏先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香生先生、陳 志峰先生、陳怡芳女士及廖啟宇先生。 * 僅供識別 (1) 董事會審核委員會由三位董事組成，即方香生先生、陳怡芳女士及廖啟宇先 生，其中方香生先生擔任董事會審核委員會主席； (2) 董事會薪酬委員會由三位董事組成，即陳志峰先生、劉毅先生及廖啟 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 二零二五年六月二十四日舉行之股東周年大會的表決結果 Sisram Medical Ltd復銳醫療科技有限公司*（「本公司」）於二零二五年六月二十四 日舉行之股東周年大會（「股東周年大會」）上，所有列載於二零二五年五月二十一 日的股東周年大會通告內的提呈決議案均以一股一票方式進行投票表決。投票表 決結果如下： | | 普通決議案 | 票數(%) | | | | --- | --- | --- | --- | --- | | | | 贊成 反對 | 棄權 | | | 1. | 省覽截至二零二四年十二月三十一日止年度的 | 221,628,662 0 | | 338,219 | | | 經審核綜合財務報表以及董事會報告及核數師 | (100.000000%) | ( ...

Core Insights - The establishment of the "Furui × Xingrong Aesthetic Innovation Research Center" marks a new phase of collaboration between Furui Medical Technology and Xingrong Plastic Surgery Hospital in the aesthetic medicine field [1][3][4] - The center aims to integrate research, development, and clinical application, focusing on the local clinical application of Furui's core product, Daxifei®, and its precise dosage solutions [3][4] Group 1 - The center will leverage Furui Medical Technology's global expertise in energy source equipment and Xingrong's rich clinical resources to create a comprehensive innovation system from basic research to product transformation [3][4] - The collaboration will introduce cutting-edge aesthetic technologies and focus on the development of new materials, techniques, and therapies [4][8] - The center aims to enhance the clinical value of aesthetic products through technology sharing and ecological collaboration, providing consumers with a personalized beauty and health experience [8] Group 2 - The center will serve as an international exchange platform, promoting the standardization of aesthetic services in China to align with international standards [4][8] - Discussions during the event included optimizing minimally invasive injection techniques and personalized injection plans for facial dynamic areas based on Daxifei®'s advantages [3][4] - The partnership is expected to continuously deepen, enhancing the clinical value of aesthetic products and fostering talent in the industry through localized innovation and training systems [8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 有關供應框架協議之 持續關連交易 供應框架協議 董事會欣然宣佈，於二零二五年六月十日，Sisram HK與復星萬邦（江蘇）訂立 供應框架協議，據此，Sisram HK同意向復星萬邦（江蘇）供應該產品，而復星 萬邦（江蘇）則同意向Sisram HK購買該產品。 該產品（注射用A型肉毒毒素(DaxibotulinumtoxinA-lanm)，中國內地商標為達 希斐®，英文商標為DAXXIFY®，項目編號RT002）為一款由復星產業再授權的 產品，用於暫時性改善成人因皺眉肌及╱或降眉間肌活動引起的中度至重度皺 眉紋。 訂立供應框架協議的理由及裨益 訂立供應框架協議符合本集團的業務模式。Sisram HK根據供應框架協議供應 該產品屬本集團的日常及一般業務過程。 此外 ...

Summary of Conference Call Records Company and Industry Overview - The conference call discusses a company listed in the Hong Kong stock market, which operates primarily in the biotechnology and medical device industry, focusing on products such as botulinum toxin and other aesthetic treatments. The company is navigating challenges related to currency fluctuations and market dynamics, particularly in North America and Israel. Key Points and Arguments Financial Performance and Currency Impact - The company acknowledges that financial performance metrics may differ due to currency exchange rates, particularly as it operates in USD while reporting in RMB. The exchange rate fluctuations can lead to discrepancies in reported growth rates and financial results [1][2]. - The company has implemented monthly hedging strategies to mitigate currency risk, ensuring that financial assessments remain accurate despite exchange rate volatility [2]. Sales Strategy and Market Positioning - The sales model has shifted towards direct sales, with a reported 87% of sales coming from this channel in 2024, reflecting a nearly 50% year-over-year increase [2]. - The company emphasizes the importance of direct sales in enhancing profit margins, as direct sales typically yield higher average selling prices (ASP) compared to distribution channels [4]. Market Dynamics and Growth Opportunities - The North American market is experiencing cyclical economic pressures, particularly due to high interest rates affecting customer purchasing behavior. However, there is optimism for a rebound in sales as interest rates are expected to decline [8][9]. - The company is exploring new product launches and market strategies to capture additional market share, particularly in the face of economic challenges [9][10]. Product Development and Regulatory Challenges - The company is in the process of launching new products, including a botulinum toxin product that has already seen significant sales in the U.S. market, achieving $100 million in sales within five quarters [14]. - Regulatory hurdles are acknowledged, with the company working through the necessary approvals for new products in various markets, including China and the U.S. [15][16]. Future Outlook and Strategic Goals - The company aims to establish a second growth curve through its aesthetic product line, with expectations for significant revenue contributions starting in 2025 [20][23]. - There is a focus on expanding product offerings and enhancing market penetration, particularly in high-demand regions such as North America and Asia [24][25]. Competitive Positioning and Product Differentiation - The company positions its products as high-end offerings, leveraging unique technologies and formulations to differentiate from competitors. This includes the use of proprietary techniques that enhance treatment efficacy and patient satisfaction [17][18]. - Feedback from healthcare professionals indicates strong market acceptance and effectiveness of the products, which supports the company's premium pricing strategy [19]. Additional Important Insights - The company is actively managing its operational costs in response to fluctuating revenues, ensuring that expenses align with income expectations [10]. - There is a strategic emphasis on building a robust pipeline of new products to sustain growth and meet evolving consumer demands in the aesthetic market [27][38]. This summary encapsulates the key discussions and insights from the conference call, highlighting the company's strategic direction, market challenges, and growth opportunities within the biotechnology and medical device industry.

復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 股東周年大會通告 茲通告Sisram Medical Ltd復銳醫療科技有限公司（* 「本公司」）謹訂於二零二五年 六月二十四日（星期二）下午二時正假座香港灣仔港灣道1號香港會議展覽中心M層 會議室3–4舉行股東周年大會（「大會」），以考慮並酌情通過下列決議案為普通決議 案： ***不提供食物，亦不提供任何公司禮品、禮券或餅卡。*** 普通決議案 – 1 – 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 不得超過本決議案通過當日本公司已發行股份總數（不包括庫存股份）的 20%（倘於本決議案通過當日之後出現任何本公司股份合併或拆細，則可 予調整）；及 – 2 – (b) 本公司根據上文(a)段授權而購回的股份總數不得超過於本決議案通過當日 本公司已發行股份總數（不包括庫存股份）的10%（倘於本決議案通過當日 ...

此 乃 要 件 請 即 處 理 閣下對本通函任何方面或應採取的行動如有任何疑問，應諮詢股票經紀或其他註冊證券商、銀行經 理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓所有名下的Sisram Medical Ltd復銳醫療科技有限公司* 股份，應立即將本通函 連同隨附的代表委任表格送交買主或承讓人或經手買賣或轉讓的銀行、股票經紀或其他代理商，以 便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部份內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 建議重選董事 及 建議授出購回股份及發行股份的一般授權 及 股東周年大會通告 ***不提供食物，亦不提供任何公司禮品、禮券或餅卡。*** Sisram Medical Ltd復銳醫療科技有限公司* 謹訂於二零二五年六月二十四日（星期二）下午二時正假 座香港灣仔港灣道1號香港會議展覽中心M層會 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of $349.1 million, a decrease of 2.3% from $359.3 million in 2023[10] - Gross profit for 2024 was $216.7 million, resulting in a gross margin of 62.1%, up from 61.1% in 2023[10] - The company achieved a net profit of $28.8 million for 2024, with a net profit margin of 8.2%, down from 9.2% in the previous year[10] - In 2024, the total revenue for the company reached $349.1 million, a decrease of 2.8% compared to 2023, primarily due to challenging economic conditions in North America and Latin America[32] - Gross profit decreased from $219.5 million in 2023 to $216.7 million in 2024, with a gross margin improvement to 62.1%, up from 61.1% in the previous year[33] - Net profit for the period was $28.8 million, a decrease of 12.6%, resulting in a net profit margin decline from 9.2% to 8.2%[33] - Adjusted net profit decreased by 22.3% from $36.9 million in 2023 to $28.7 million in 2024, with an adjusted net profit margin of 8.2%[80] Assets and Liabilities - Total assets increased to $627.3 million in 2024, compared to $613.5 million in 2023, while total liabilities slightly decreased to $142.5 million[11] - As of December 31, 2024, cash and cash equivalents exceeded total debt, indicating no leverage ratio was presented[82] - Total interest-bearing bank and other borrowings amounted to $4.8 million as of December 31, 2024, compared to $4.4 million in 2023[85] Revenue by Region - The Asia-Pacific region generated $116.2 million in revenue, reflecting a 6.0% increase year-over-year, while Europe and the Middle East & Africa reported revenues of $50.5 million and $34.6 million, growing 0.7% and 27.1% respectively[20] - North America revenue fell by 12.4% to $137.4 million, primarily due to the impact of high interest rates on financing costs for customers[69] - Asia-Pacific revenue increased by 6.0% to $116.2 million, driven by the successful implementation of the "Go-Direct" strategy and expansion of operations in Thailand, China, and Japan[69] Product Development and Innovation - The company received approval for its injectable botulinum toxin product DAXXIFY® in China, expected to launch in 2025, enhancing its growth potential[15] - The company is focusing on integrating AI technologies into its offerings, launching the Alma IQ™ skin analysis solution to provide comprehensive beauty health solutions[15] - The company launched three new products, including Alma Harmony™, Soprano Titanium™ special edition, and Alma IQ™, which received strong market recognition[41] - The company successfully launched Profhilo® in Thailand, showcasing its ability to integrate injection fillers with energy-based devices for combined treatment solutions[27] - The new generation hyaluronic acid complex Profhilo® received approval from the Hainan Provincial Drug Administration in April 2024, crucial for its commercialization in mainland China[43] Sales and Distribution - Direct sales accounted for 87% of total revenue, while distribution contributed 13%, demonstrating the effectiveness of the company's strategy in a challenging macro environment[22] - The gross profit from direct sales accounted for 87% of total revenue, compared to 78% in the same period last year[33] - The company achieved a nearly 20% growth in direct sales offices outside North America, balancing revenue performance amid regional challenges[32] Strategic Initiatives - The company aims to enhance its core business profitability and accelerate the commercialization of key products in 2024[17] - The company is pursuing a localization strategy to better meet local market demands through integrated production, research, and sales[16] - The company is strategically investing in expanding its ecosystem through diversified business lines and consumer brands[38] - The company is pursuing mergers and acquisitions to enhance its R&D capabilities and product portfolio[60] Corporate Governance - The board consists of a balanced mix of executive and non-executive directors, ensuring strong independence and effective decision-making[175] - The company’s board is collectively responsible for overseeing the business and ensuring effective internal controls and risk management systems[185] - The board has the authority to make decisions on significant matters, including policies, strategies, and major transactions[186] - The company emphasizes compliance with regulatory requirements and has allocated resources to ensure ongoing adherence to relevant rules and regulations[162] Employee and Workforce - Employee headcount decreased by 5.9%, resulting in a reduction of 64 employees, totaling 1,015 employees as of December 31, 2024[109] - Research and development activities were conducted by 84 employees, accounting for 23.6% of the total workforce[110] - The company has a robust employee training program to enhance understanding of market and industry developments, ensuring a competitive work environment[166] Environmental and Social Responsibility - The company is committed to environmental sustainability and has implemented measures to improve manufacturing and development environmental performance, including reducing carbon emissions[163] Financial Management - Cash flow from operating activities, investing activities, and financing activities was utilized for operational needs, interest payments, and capital expenditures[88] - Net cash flow from operating activities for the reporting period was $33.1 million, a decrease of 24.7% compared to the previous year[91] - Capital expenditures for the reporting period amounted to $2.7 million, primarily for the renovation of leased properties[94] Shareholder Information - Major shareholders include Meizhong Huli with 127,318,640 shares (27.18%) and Nengyue with 207,186,160 shares (44.24%)[139] - The company reported a final dividend of HKD 0.126 per share for the year ended December 31, 2024[114] Compliance and Legal Matters - The company has not been involved in any significant litigation or arbitration as of December 31, 2024[165] - The company has complied with all disclosure requirements under Chapter 14A of the listing rules during the reporting period[155]

Investment Rating - The investment rating for the company is upgraded to "Buy" with a target price not specified [5]. Core Viewpoints - The company reported a revenue of 2.51 billion RMB for 2024, a decrease of 2.8% year-on-year, and a net profit of 181 million RMB, down 12.6% year-on-year [1]. - Direct sales strategy has improved profitability, with direct sales accounting for 87% of total sales in 2024, an increase of 9 percentage points year-on-year [2]. - The company has received EU medical device certification, enhancing its brand advantage and allowing the launch of three core products in new markets [3]. - The product range is expanding to include various beauty and health applications, with new products launched in multiple regions [4]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 2.51 billion RMB, a decline of 2.8% compared to the previous year, and a net profit of 181 million RMB, down 12.6% [1]. Sales Strategy - The direct sales strategy has been effective, with 87% of sales coming from direct channels, reflecting a 9 percentage point increase from the previous year. Revenue from the Asia-Pacific, Europe, Middle East, and Africa regions grew by 6.0%, 0.7%, and 27.1% respectively, while North America saw a decline of 12.4% due to high financing costs [2]. Product Development - The company has focused on energy source technology for medical aesthetics, achieving EU medical device certification for several products. Three new core products were launched in 2024, receiving high market recognition [3]. Product Range Expansion - The company is diversifying its product offerings, including a new generation of hyaluronic acid complex and exclusive distribution rights for various injection fillers. The expansion includes markets in the UK, Germany, Australia, and New Zealand [4].